These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 22535592)

  • 41. Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.
    Rozman M; Navarro JT; Arenillas L; Aventín A; Giménez T; Alonso E; Perea G; Camós M; Navarrete M; Tuset E; Florensa L; Millá F; Nomdedéu J; de la Banda E; Díaz-Beyá M; Pratcorona M; Garrido A; Navarro B; Brunet S; Sierra J; Esteve J;
    Ann Hematol; 2014 Oct; 93(10):1695-703. PubMed ID: 24824767
    [TBL] [Abstract][Full Text] [Related]  

  • 42. AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients.
    Alpermann T; Haferlach C; Eder C; Nadarajah N; Meggendorfer M; Kern W; Haferlach T; Schnittger S
    Leuk Res; 2015 Mar; 39(3):265-72. PubMed ID: 25592059
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML.
    Hollink IH; Zwaan CM; Zimmermann M; Arentsen-Peters TC; Pieters R; Cloos J; Kaspers GJ; de Graaf SS; Harbott J; Creutzig U; Reinhardt D; van den Heuvel-Eibrink MM; Thiede C
    Leukemia; 2009 Feb; 23(2):262-70. PubMed ID: 19020547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Subtype-specific patterns of molecular mutations in acute myeloid leukemia.
    Rose D; Haferlach T; Schnittger S; Perglerová K; Kern W; Haferlach C
    Leukemia; 2017 Jan; 31(1):11-17. PubMed ID: 27285584
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prospective study of 174 de novo acute myelogenous leukemias according to the WHO classification: subtypes, cytogenetic features and FLT3 mutations.
    Bao L; Wang X; Ryder J; Ji M; Chen Y; Chen H; Sun H; Yang Y; Du X; Kerzic P; Gross SA; Yao L; Lv L; Fu H; Lin G; Irons RD
    Eur J Haematol; 2006 Jul; 77(1):35-45. PubMed ID: 16573742
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia.
    Fuster O; Barragán E; Bolufer P; Such E; Valencia A; Ibáñez M; Dolz S; de Juan I; Jiménez A; Gómez MT; Buño I; Martínez J; Cervera J; Montesinos P; Moscardó F; Sanz MÁ
    Ann Hematol; 2012 Jan; 91(1):1-7. PubMed ID: 21538063
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population.
    Ahmad F; Mandava S; Das BR
    Hematol Oncol; 2009 Jun; 27(2):90-7. PubMed ID: 19365794
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
    Dufour A; Schneider F; Hoster E; Benthaus T; Ksienzyk B; Schneider S; Kakadia PM; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Subklewe M; Hiddemann W; Bohlander SK; Spiekermann K;
    Ann Hematol; 2012 Jul; 91(7):1051-63. PubMed ID: 22362118
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Persistence of DNMT3A mutations at long-term remission in adult patients with AML.
    Pløen GG; Nederby L; Guldberg P; Hansen M; Ebbesen LH; Jensen UB; Hokland P; Aggerholm A
    Br J Haematol; 2014 Nov; 167(4):478-86. PubMed ID: 25371149
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Establishment of a rapid and easy method for simultaneous detection of FLT3-ITD and NPM1 gene mutations in acute myeloid leukemia].
    Lu Y; Wang Q; Mu QT; Yu MX; Huang Q; Jin J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Apr; 29(2):163-6. PubMed ID: 22487825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia.
    Del Poeta G; Ammatuna E; Lavorgna S; Capelli G; Zaza S; Luciano F; Ottone T; Del Principe MI; Buccisano F; Maurillo L; Panetta P; de Fabritiis P; Stasi R; Venditti A; Amadori S; Lo Coco F
    Br J Haematol; 2010 May; 149(3):383-7. PubMed ID: 20148885
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia.
    Falini B; Martelli MP
    Best Pract Res Clin Haematol; 2015; 28(2-3):90-7. PubMed ID: 26590764
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
    Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
    Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome.
    Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Guo R; Tierens A; Minden MD; Chang H
    Hum Pathol; 2020 Oct; 104():117-126. PubMed ID: 32798550
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.
    Ohgami RS; Ma L; Merker JD; Gotlib JR; Schrijver I; Zehnder JL; Arber DA
    Mod Pathol; 2015 May; 28(5):706-14. PubMed ID: 25412851
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias.
    Carbuccia N; Trouplin V; Gelsi-Boyer V; Murati A; Rocquain J; Adélaïde J; Olschwang S; Xerri L; Vey N; Chaffanet M; Birnbaum D; Mozziconacci MJ
    Leukemia; 2010 Feb; 24(2):469-73. PubMed ID: 19865112
    [No Abstract]   [Full Text] [Related]  

  • 57. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.
    Mason EF; Hasserjian RP; Aggarwal N; Seegmiller AC; Pozdnyakova O
    Blood Adv; 2019 Nov; 3(21):3322-3332. PubMed ID: 31698462
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated
    Nguyen L; Zhang X; Roberts E; Yun S; McGraw K; Abraham I; Song J; Braswell D; Qin D; Sallman DA; Lancet JE; List AF; Moscinski LC; Padron E; Zhang L
    Leuk Lymphoma; 2020 Jun; 61(6):1395-1405. PubMed ID: 32091281
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical implications of
    Tan M; Ng IKS; Chen Z; Ban K; Ng C; Chiu L; Seah E; Lin M; Tai BC; Yan B; Ng CH; Chng WJ
    J Clin Pathol; 2017 Aug; 70(8):669-676. PubMed ID: 28100593
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system.
    Weinberg OK; Seetharam M; Ren L; Seo K; Ma L; Merker JD; Gotlib J; Zehnder JL; Arber DA
    Blood; 2009 Feb; 113(9):1906-8. PubMed ID: 19131546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.